Article
Neoadjuvant therapy-associated malignant phenotype score predicts prognosis and highlights the roles of MIF signaling and DUXAP8 in ESCC.
Frontiers in immunology - 1 Jan 2025
Xia Wenchao, Lin Tan, Shi Mengnan, Mu Qiuqiao, Zhang Han, Xu Yijun
Abstract excerpt
Background: Esophageal squamous cell carcinoma (ESCC) remains a major malignancy globally, and long-term survival outcomes remain poor despite advances in multimodal treatment strategies. Neoadjuvant therapy (NAT) has become the standard of care for resectable ESCC; however, substantial interpatient heterogeneity in treatment response persists. Defining malignant cell-intrinsic molecular determinants linked to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
